Needle- Free Diabetes Care Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
Overview
Needle- Free Diabetes Care Market was valued at US$23.82 Bn in 2032. Needle- Free Diabetes Care Market size is expected to grow at a CAGR of 7.74% through the forecast period.
Needle- Free Diabetes Care Market Overview:
Diabetes is a metabolic disorder in which person has high blood glucose levels than the normal blood glucose. Because of inadequate insulin production or body cells are unable to respond to the produced insulin in the body.
To know about the Research Methodology:- Request Free Sample Report
The report explores the Needle- Free Diabetes Care Market's segments (Connectivity and Content, and Region). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2020. The report investigates the Needle- Free Diabetes Care Market's drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Needle- Free Diabetes Care Market's contemporary competitive scenario.
Needle- Free Diabetes Care Market Dynamics:
The rise of the geriatric population, the prevalence of diabetes, and the introduction of technological breakthroughs are all contributing to the global needle-free diabetes care market's expansion. To ensure greater healthcare efficiency and productivity, the development of technologically advanced diabetes management devices is becoming important. Diabetic patients must currently prick their fingertips to take blood samples in order to monitor their blood glucose levels. The industry is projected to develop as people become more aware of the safety risks associated with needles. Furthermore, because to the advancement of sophisticated biosensors, glucose monitoring devices are becoming more user-friendly and painless. It can be used at home and allows patients to conveniently check their blood glucose levels.
With the development of sophisticated insulin jet injectors, diabetes treatment has recently become needle-free. The cutting-edge technologies allow patients to self-inject medications without pain.
Insulin prices are becoming a barrier to treatment in most low- and middle-income countries around the world, despite a substantial supply. Furthermore, during the projection period, advancements such as the artificial pancreas and home infusion therapy are likely to generate considerable potential prospects.
Needle- Free Diabetes Care Market Segment Analysis:
The needle-free diabetes care market is segmented on the basis of type of device, end-user, and region. Based on the type of device, the market is categorized as diagnostic devices and treatment devices. On the basis of end-user, the market is categorized as hospitals and clinics, diagnostic centres and consumer.
Needle- Free Diabetes Care Market Regional Insights:
North America dominates the needle-free diabetes care market because of the large diabetic population, changing lifestyle, increasing healthcare expenditure and rise in the number of obese people. The Asia Pacific market is projected to expand at a high growth rate due to growing health care expenditure and high patient base.
The market in Europe is growing at a significant rate due to increasing R&D investment in the field of diabetes and awareness among the population toward the disease.
Needle- Free Diabetes Care Market Recent Developement
| Exact Date | Company | Development | Impact |
|---|---|---|---|
| 02 February 2026 | Medtronic plc | The company secured FDA clearance for its MiniMed 780G system to integrate with the Instinct sensor (developed by Abbott) for Type 2 diabetes patients. | This expansion provides Medicare beneficiaries access to the world’s smallest and thinnest integrated CGM, enhancing automated insulin delivery for a broader patient base. |
| 12 January 2026 | Medtronic Diabetes | Medtronic received FDA 510(k) clearance for the MiniMed Go Smart MDI system, featuring the needle-free Instinct CGM sensor. | The system automates insulin dosing data and glucose tracking in a single app, significantly reducing diabetes distress for users on multiple daily injections. |
| 06 November 2025 | IIT Madras | Researchers patented a minimally invasive CGM device featuring a patented electro-thermochromic display that shows glucose levels directly on the patch. | By eliminating the need for external gadgets or smartphones, the device improves affordability and user autonomy for long-term diabetes management. |
| 21 October 2025 | PharmaJet | PharmaJet announced the expansion of its needle-free technology into the self-injection pen market for subcutaneous chronic disease treatments. | The new reusable needle-free pens aim to overcome needle aversion and injection site pain, targeting the high-growth metabolic peptide market. |
| 24 September 2025 | Portal Instruments | The company expanded its strategic partnership with Gerresheimer to commercialize the PRIME Nexus reusable, connected needle-free autoinjector platform. | This collaboration leverages mass-scale manufacturing to provide a sustainable and digitalized delivery solution for high-viscosity biologic therapies. |
| 21 August 2025 | NuGen Medical Devices | NuGen unveiled a next-generation needle-free injection system featuring internal cartridge technology to eliminate manual insulin drawing. | By embedding prefilled cartridges, the device simplifies the subcutaneous delivery workflow, reducing dosing errors and improving patient compliance. |
Needle- Free Diabetes Care Market Scope: Inquire before buying
| Needle- Free Diabetes Care Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 14.14 USD Bn |
| Forecast Period 2026-2032 CAGR: | 7.74% | Market Size in 2032: | 23.82 USD Bn |
| Segments Covered: | by Devices | Treatment devices Insulin patches Jet injectors Insulin pens Insulin pumps Insulin infuser Diagnostic devices Continuous glucose monitoring Instant glucose monitoring |
|
| by Device Types Outlook | Diagnostic devices Instant glucose monitoring Continuous glucose monitoring Treatment devices Insulin pen Insulin patch Insulin pump Insulin inhaler Insulin jet injector |
||
| by Application Outlook | Insulin delivery Others |
||
| by End User | Diagnostic Centers Hospitals and Clinics Consumer |
||
Needle- Free Diabetes Care Market, by Region
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
Needle- Free Diabetes Care Market Key Players
• Anatres pharma
• European Pharma Group
• Johnson and Johnson
• Injex UK Ltd
• Bioject Medical Technologies Inc.
• PharmaJet
• MannKind Corporation
• Tandem Diabetes Care
• Medtronic
• Pancreum LLC
• Glide Pharmaceutical Technologies Ltd
• Zogenix
• Akra Dermojet
• Echo Therapeutics
• 3M
• Medical International Technology Inc.
• National Medical Products Inc.
• Penjet Corporation